{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T22:41:12Z","timestamp":1764715272735,"version":"build-2065373602"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100001797","name":"Pharmaceutical Research and Manufacturers of America Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007698","name":"University of Florida","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007698","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40256-025-00745-w","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T13:59:53Z","timestamp":1752242393000},"page":"741-748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Efficacy of Pharmacological Interventions for Heart Failure with Reduced Ejection Fraction Between Asian and White Patients: A Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"25","author":[{"given":"Wenxi","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huilin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Han","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao-Hsuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Bian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa M","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen E","family":"Kimmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9799-2592","authenticated-orcid":false,"given":"Jingchuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"issue":"1","key":"745_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ehf2.12005","volume":"1","author":"P Ponikowski","year":"2014","unstructured":"Ponikowski P, Anker SD, AlHabib KF, et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1(1):4\u201325. https:\/\/doi.org\/10.1002\/ehf2.12005.","journal-title":"ESC Heart Fail."},{"key":"745_CR2","unstructured":"American Heart Association. Heart failure signs and symptoms. https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/warning-signs-of-heart-failure. Accessed 8 Aug 2024."},{"issue":"1","key":"745_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","volume":"3","author":"G Savarese","year":"2017","unstructured":"Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3(1):7\u201311. https:\/\/doi.org\/10.15420\/cfr.2016:25:2.","journal-title":"Card Fail Rev"},{"issue":"5","key":"745_CR4","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/jama.2020.10262","volume":"324","author":"SP Murphy","year":"2020","unstructured":"Murphy SP, Ibrahim NE, Januzzi JL. Heart failure with reduced ejection fraction: a review. JAMA. 2020;324(5):488\u2013504. https:\/\/doi.org\/10.1001\/jama.2020.10262.","journal-title":"JAMA"},{"issue":"17","key":"745_CR5","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263\u2013421. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.012.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"745_CR6","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","volume":"273","author":"R Garg","year":"1995","unstructured":"Garg R, Yusuf S, Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273(18):1450\u20136.","journal-title":"JAMA"},{"issue":"23","key":"745_CR7","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667\u201375. https:\/\/doi.org\/10.1056\/NEJMoa010713.","journal-title":"N Engl J Med"},{"issue":"9146","key":"745_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"CIBIS-II Investigators and Committees","year":"1999","unstructured":"CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9\u201313.","journal-title":"Lancet"},{"issue":"10","key":"745_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Randomized Aldactone Evaluation Study Investigators, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709\u201317. https:\/\/doi.org\/10.1056\/NEJM199909023411001.","journal-title":"N Engl J Med"},{"issue":"10254","key":"745_CR10","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet Lond Engl. 2020;396(10254):819\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(20)31824-9.","journal-title":"Lancet Lond Engl."},{"issue":"11","key":"745_CR11","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1001\/jama.2019.12843","volume":"322","author":"AS Desai","year":"2019","unstructured":"Desai AS, Solomon SD, Shah AM, et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2019;322(11):1077\u201384. https:\/\/doi.org\/10.1001\/jama.2019.12843.","journal-title":"JAMA"},{"issue":"10","key":"745_CR12","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1001\/jamacardio.2018.2559","volume":"3","author":"AS Tahhan","year":"2018","unstructured":"Tahhan AS, Vaduganathan M, Greene SJ, et al. Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials: a systematic review. JAMA Cardiol. 2018;3(10):1011. https:\/\/doi.org\/10.1001\/jamacardio.2018.2559.","journal-title":"JAMA Cardiol."},{"issue":"5","key":"745_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/ejhf.1347","volume":"21","author":"P Dewan","year":"2019","unstructured":"Dewan P, Jhund PS, Shen L, et al. Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. Eur J Heart Fail. 2019;21(5):577\u201387. https:\/\/doi.org\/10.1002\/ejhf.1347.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"745_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.cardfail.2017.01.004","volume":"23","author":"J Rajadurai","year":"2017","unstructured":"Rajadurai J, Tse HF, Wang CH, et al. Understanding the epidemiology of heart failure to improve management practices: an Asia-Pacific perspective. J Card Fail. 2017;23(4):327\u201339. https:\/\/doi.org\/10.1016\/j.cardfail.2017.01.004.","journal-title":"J Card Fail"},{"key":"745_CR15","unstructured":"Higgins J, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). https:\/\/training.cochrane.org\/handbook. Accessed 12 Aug 2024."},{"issue":"7414","key":"745_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"issue":"11","key":"745_CR17","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358. https:\/\/doi.org\/10.1002\/sim.1186.","journal-title":"Stat Med"},{"issue":"2","key":"745_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/jrsm.57","volume":"3","author":"A Chaimani","year":"2012","unstructured":"Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods. 2012;3(2):161\u201376. https:\/\/doi.org\/10.1002\/jrsm.57.","journal-title":"Res Synth Methods."},{"issue":"5","key":"745_CR19","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.2337\/dc20-3007","volume":"44","author":"MMY Lee","year":"2021","unstructured":"Lee MMY, Ghouri N, McGuire DK, et al. Meta-analyses of results from randomized outcome trials comparing cardiovascular effects of SGLT2is and GLP-1RAs in Asian versus White Patients with and without type 2 diabetes. Diabetes Care. 2021;44(5):1236\u201341. https:\/\/doi.org\/10.2337\/dc20-3007.","journal-title":"Diabetes Care"},{"issue":"9","key":"745_CR20","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.2337\/dc13-2966","volume":"37","author":"UE Ntuk","year":"2014","unstructured":"Ntuk UE, Gill JMR, Mackay DF, et al. Ethnic-specific obesity cutoffs for diabetes risk: cross-sectional study of 490,288 UK biobank participants. Diabetes Care. 2014;37(9):2500\u20137. https:\/\/doi.org\/10.2337\/dc13-2966.","journal-title":"Diabetes Care"},{"issue":"8","key":"745_CR21","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1007\/s00125-020-05169-6","volume":"63","author":"AK Wright","year":"2020","unstructured":"Wright AK, Welsh P, Gill JMR, et al. Age-, sex- and ethnicity-related differences in body weight, blood pressure, HbA1c and lipid levels at the diagnosis of type 2 diabetes relative to people without diabetes. Diabetologia. 2020;63(8):1542\u201353. https:\/\/doi.org\/10.1007\/s00125-020-05169-6.","journal-title":"Diabetologia"},{"issue":"4","key":"745_CR22","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.dsx.2020.04.051","volume":"14","author":"AK Singh","year":"2020","unstructured":"Singh AK, Singh R. Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Diabetes Metab Syndr. 2020;14(4):715\u201322. https:\/\/doi.org\/10.1016\/j.dsx.2020.04.051.","journal-title":"Diabetes Metab Syndr"},{"issue":"21","key":"745_CR23","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"issue":"2","key":"745_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jacasi.2022.02.004","volume":"2","author":"KF Docherty","year":"2022","unstructured":"Docherty KF, Anand IS, Chiang CE, et al. Effects of dapagliflozin in Asian patients with heart failure and reduced ejection fraction in DAPA-HF. JACC Asia. 2022;2(2):139\u201353. https:\/\/doi.org\/10.1016\/j.jacasi.2022.02.004.","journal-title":"JACC Asia."},{"issue":"11","key":"745_CR25","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.120.047077","volume":"142","author":"AM Jackson","year":"2020","unstructured":"Jackson AM, Dewan P, Anand IS, et al. Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation. 2020;142(11):1040\u201354. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.047077.","journal-title":"Circulation"},{"issue":"9","key":"745_CR26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1089\/met.2021.0016","volume":"19","author":"MS Malik","year":"2021","unstructured":"Malik MS, Malik M, Sukhera AB, et al. Metabolic syndrome and related inflammation, prevalence, and predictive value of C-reactive protein in South Asian youths. Metab Syndr Relat Disord. 2021;19(9):483\u201390. https:\/\/doi.org\/10.1089\/met.2021.0016.","journal-title":"Metab Syndr Relat Disord"},{"issue":"4","key":"745_CR27","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3945\/ajcn.2008.27080","volume":"89","author":"TW McDade","year":"2009","unstructured":"McDade TW, Rutherford JN, Adair L, Kuzawa C. Population differences in associations between C-reactive protein concentration and adiposity: comparison of young adults in the Philippines and the United States. Am J Clin Nutr. 2009;89(4):1237\u201345. https:\/\/doi.org\/10.3945\/ajcn.2008.27080.","journal-title":"Am J Clin Nutr"},{"issue":"11","key":"745_CR28","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1001\/jama.2013.1954","volume":"309","author":"M Gheorghiade","year":"2013","unstructured":"Gheorghiade M, B\u00f6hm M, Greene SJ, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013;309(11):1125. https:\/\/doi.org\/10.1001\/jama.2013.1954.","journal-title":"JAMA"},{"issue":"15","key":"745_CR29","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"issue":"12","key":"745_CR30","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam MA. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319. https:\/\/doi.org\/10.1001\/jama.297.12.1319.","journal-title":"JAMA"},{"issue":"1","key":"745_CR31","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1253\/circj.CJ-17-0323","volume":"82","author":"H Tsutsui","year":"2018","unstructured":"Tsutsui H, Ito H, Kitakaze M, et al. Double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of eplerenone in Japanese patients with chronic heart failure (J-EMPHASIS-HF). Circ J. 2018;82(1):148\u201358. https:\/\/doi.org\/10.1253\/circj.CJ-17-0323.","journal-title":"Circ J"},{"issue":"10","key":"745_CR32","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1253\/circj.CJ-19-0227","volume":"83","author":"H Tsutsui","year":"2019","unstructured":"Tsutsui H, Momomura S-I, Yamashina A, et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure\u2014J-SHIFT Study. Circ J. 2019;83(10):2049\u201360. https:\/\/doi.org\/10.1253\/circj.CJ-19-0227.","journal-title":"Circ J"},{"issue":"10","key":"745_CR33","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","volume":"283","author":"\u00c5 Hjalmarson","year":"2000","unstructured":"Hjalmarson \u00c5, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA. 2000;283(10):1295. https:\/\/doi.org\/10.1001\/jama.283.10.1295.","journal-title":"JAMA"},{"issue":"6","key":"745_CR34","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ihj.2020.09.016","volume":"72","author":"AR Jain","year":"2020","unstructured":"Jain AR, Aggarwal RK, Rao NS, et al. Efficacy and safety of sacubitril\/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF India sub-study. Indian Heart J. 2020;72(6):535\u201340. https:\/\/doi.org\/10.1016\/j.ihj.2020.09.016.","journal-title":"Indian Heart J"},{"issue":"11","key":"745_CR35","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS, et al. Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077.","journal-title":"N Engl J Med"},{"issue":"3","key":"745_CR36","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3760\/cma.j.issn.0253-3758.2017.03.005","volume":"45","author":"DY Hu","year":"2017","unstructured":"Hu DY, Huang DJ, Yuan ZY, et al. Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study. Zhonghua Xin Xue Guan Bing Za Zhi. 2017;45(3):190\u20137. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-3758.2017.03.005.","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"10","key":"745_CR37","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1056\/NEJM199209033271003","volume":"327","author":"S Yusuf","year":"1992","unstructured":"SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327(10):685\u201391. https:\/\/doi.org\/10.1056\/NEJM199209033271003.","journal-title":"N Engl J Med"},{"issue":"20","key":"745_CR38","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883\u201393. https:\/\/doi.org\/10.1056\/NEJMoa1915928.","journal-title":"N Engl J Med"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00745-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00745-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00745-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:08:24Z","timestamp":1762528104000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00745-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["745"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00745-w","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"type":"print","value":"1175-3277"},{"type":"electronic","value":"1179-187X"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"assertion":[{"value":"18 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PhRMA Foundation Research Starter Award (PI: Guo) and University of Florida Research Opportunity Seed Fund (PI: Guo).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Guo received a consulting fee from Pfizer, outside the current work. Wenxi Huang, Huilin Tang, Yujia Li, Wei-Han Chen, Shao-Hsuan Chang, Jiang Bian, Mustafa M Ahmed, and Stephen Kimmel declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Conceptualization: JG. Methodology: WH, HT, and JG. Formal analysis: WH, HT, YL, WC, and SC. Resources: JG. Writing\u2014initial draft: WH. Writing\u2014review and editing: WH, HT, YL, WC, SC, JB, MA, SK, and JG. Supervision: JG. All authors have read and agreed to the published version of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}